BriaCell Therapeutics Corp. (BCTX) intrinsic value & 10-year financials
BriaCell Therapeutics Corp. (BCTX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.40
- Market cap
- $1.4M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -216.6%
- Free cash flow (FY2025)
- —
BCTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$26.3M | -$62.19 | — | — | -359.2% |
| FY2024 | — | -$4.8M | -$0.29 | -$24.6M | — | 148.3% |
| FY2023 | — | -$20.3M | -$1.30 | — | — | -619.8% |
| FY2022 | — | -$26.8M | -$1.73 | — | — | -141.3% |
| FY2021 | — | -$13.8M | — | — | — | -110.8% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BriaCell Therapeutics Corp. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BriaCell Therapeutics Corp. has historically struggled to out-earn its cost of capital, averaging just -22.7% ROIC.
BriaCell Therapeutics Corp. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
BriaCell Therapeutics Corp. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.